Vera Q3: First TRUTAKNA Revenue of $10.3M, Net Loss Narrows to $93.7M
VERA sits 35% above its 52-week low of $23.05.
Summary
Vera reported its first TRUTAKNA revenue of $10.3 million in Q3 2026 with about 700 Patient Start Forms, and a net loss of $93.7 million that beat the $117.1 million consensus. Cash of $384.0 million plus a $75 million October debt draw leaves $459 million pro forma.
Key Events · Earnings and Guidance · VERA
-
First TRUTAKNA Revenue: $10.3M
Net product revenue of $10.3 million in Q3 2026, the first quarter with product sales, versus none a year earlier. Approximately 700 Patient Start Forms received since the July 7, 2026 accelerated approval.
-
Net Loss Beats Consensus
Net loss of $93.7 million, or $1.30 per share, versus the IBES estimate of -$117.1 million. SG&A rose to $61.4 million from $27.5 million on launch investment, while R&D fell to $41.3 million from $56.5 million as commercial manufacturing costs moved to inventory.
-
Cash and Debt Capacity
Cash, cash equivalents and marketable securities of $384.0 million at September 30, 2026; $459 million pro forma after the $75 million October draw. Up to $350 million remains available under the debt facility, subject to conditions.
-
sBLA Filed for Full Approval
Supplemental BLA for full approval in adults with primary IgAN submitted November 3, 2026, based on ORIGIN 3 final efficacy. Potential full approval expected mid-2027; EMA Marketing Authorisation Application planned for Q1 2027.
Analysis · VERA · Life Sciences
The investment case now hinges on converting IgAN patients onto TRUTAKNA, and the first quarter of commercial sales offers early evidence: $10.3 million in net product revenue and roughly 700 Patient Start Forms since the July 7 accelerated approval. The $93.7 million net loss came in well below the $117.1 million consensus estimate, while SG&A of $61.4 million versus $27.5 million a year ago confirms the launch spend is real. Cash of $384.0 million plus the $75 million October debt draw gives $459 million pro forma, with up to $350 million still available under the facility. That runway funds both the launch and the sBLA filed November 3 for full approval, which management expects to resolve in mid-2027.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VERA was trading at $31.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $23.05 to $56.05. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.